ACAD Earnings & Financial Statements
ACADIA Pharmaceuticals Inc.
$19.71
+$0.46(+2.39%)
50
Overall
75
Value
9
Tech
68
Quality
Market Cap
$3.32B
Volume
1.77M
52W Range
$19.32 - $30.96
Target Price
$32.10
ACAD earnings and financial statements: ACADIA Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ACAD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.07B | $957.80M | $726.44M | $517.24M | $484.14M |
| Cost of revenue | $89.00M | $81.84M | $41.64M | $10.17M | $19.14M |
| Operating income | $104.81M | $230.79M | -$73.38M | -$223.60M | -$170.44M |
| EBITDA | $118.97M | $248.48M | -$62.68M | -$211.44M | -$167.09M |
| Net income | $391.00M | $226.45M | -$61.29M | -$215.97M | -$167.87M |
| EPS (diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.56B | $1.19B | $748.96M | $587.81M | $700.12M |
| Total liabilities | $336.81M | $454.96M | $317.20M | $187.40M | $159.23M |
| Shareholders’ equity | $1.23B | $732.79M | $431.75M | $400.41M | $540.89M |
| Cash and equivalents | $177.69M | $319.59M | $188.66M | $114.85M | $147.44M |
| Long-term debt | $40.55M | $42.04M | $47.80M | $52.70M | $56.13M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $109.84M | $157.72M | $16.70M | -$114.03M | -$125.66M |
| Capital expenditure | -$103.53M | -$523.0K | -$40.05M | - | -$1.12M |
| Free cash flow | $6.31M | $157.20M | -$23.35M | -$114.03M | -$126.78M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACAD | $19.71 | +2.4% | 1.77M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ACADIA Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW